Review

Nanotargeted agents: an emerging therapeutic strategy for breast cancer

Manling Du^‡

College of Pharmacy, Jinan University, Guangzhou 510632, PR China

‡Authors contributed equally

Search for more papers by this author

Yong Ouyang^‡

Guangzhou Hospital of Integrated Traditional Chinese & Western Medicine, Guangzhou 510800, PR China

‡Authors contributed equally

Search for more papers by this author

Fansu Meng^‡

Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of TCM, Zhongshan, Guangdong 528400, PR China

‡Authors contributed equally

Search for more papers by this author

Qianqian Ma

College of Pharmacy, Jinan University, Guangzhou 510632, PR China

Search for more papers by this author

Hui Liu

College of Pharmacy, Jinan University, Guangzhou 510632, PR China

Search for more papers by this author

Yong Zhuang

College of Pharmacy, Jinan University, Guangzhou 510632, PR China

Search for more papers by this author

Mujuan Pang

College of Pharmacy, Jinan University, Guangzhou 510632, PR China

Search for more papers by this author

Tiange Cai

*Author for correspondence:

E-mail Address: caitiange@163.com

College of Life Sciences, Liaoning University, Shenyang 110036, PR China

Search for more papers by this author

Yu Cai

**Author for correspondence:

E-mail Address: caiyu8@sohu.com

College of Pharmacy, Jinan University, Guangzhou 510632, PR China

Cancer Research Institute of Jinan University, Guangzhou 510632, PR China

Search for more papers by this author

Published Online:12 Jul 2019https://doi.org/10.2217/nnm-2018-0481

View article

Abstract

Breast cancer is the most common female cancer worldwide and represents 12% of all cancer cases. Improvements in survival rates are largely attributed to improved screening and diagnosis. Conventional chemotherapy remains an important treatment option but it is beset with poor cell selectivity, serious side effects and resistance. Nanoparticle drug delivery systems bring promising opportunities to breast cancer treatment. They may improve chemotherapy by targeting drugs to tumors, generating high drug concentrations at tumors providing slow release of the drug, increased drug stability and concomitant reductions in side effects. The nanotechnology-based drug delivery approaches and the current research and application status of nano-targeted agents for breast cancer are discussed in this review to provide a basis for further study on targeted drug delivery systems.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Jain V, Jain S, Mahajan SC. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr. Drug Deliv. 12(2), 177–191 (2015).Crossref, Medline, CAS, Google Scholar
2. Adair JH, Parette MP, Altınoglu EI, Kester M. Nanoparticulate alternatives for drug delivery. ACS Nano 4(9), 4967–4970 (2010).Crossref, Medline, CAS, Google Scholar
3. Langer R. Polymer-controlled drug delivery systems. Acc. Chem. Res. 26(10), 537–542 (1993).Crossref, CAS, Google Scholar
4. Periasamy VS, Athinarayanan J, Alshatwi AA. Anticancer activity of an ultrasonic nanoemulsion formulation of Nigella sativa L. essential oil on human breast cancer cells. Ultrason. Sonochem. 31, 449–455 (2016).Crossref, Medline, CAS, Google Scholar
5. Talegaonkar S, Negi LM. Nanoemulsion in drug targeting. In: Targeted Drug Delivery: Concepts and Design. Springer International Publishing, Basel, Switzerland, 433–459 (2015).Crossref, Google Scholar
6. Dos Santos Camara AL, Nagel G, Tschiche HR et al. Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. Nanomedicine (Lond.) 12(15), 1751–1765 (2017).Link, Google Scholar
7. Gao Y, Zhang W, Sun T. Local transdermal delivery of 10,11-methylenedioxycamptothecin by nanoemulsion for breast cancer prevention. J. Control Rel. 259, e180–e181 (2017).Crossref, Google Scholar
8. Wang Y, Wen Q, Choi S. FDA’s regulatory science program for generic PLA/PLGA-based drug products. Am. Pharm. Rev. 19(4), 5–9 (2016).Google Scholar
9. Lee BK, Yun Y, Park K. PLA micro- and nano-particles. Adv. Drug Deliv. Rev. 107, 176–191 (2016).Crossref, Medline, CAS, Google Scholar
10. Cai C, Xie Y, Wu L et al. PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. Sci. Rep. 7, 46250 (2017).Crossref, Medline, CAS, Google Scholar
11. Elsabahy M, Wooley KL. Data mining as a guide for the construction of cross-linked nanoparticles with low immunotoxicity via control of polymer chemistry and supramolecular assembly. Acc. Chem. Res. 48(6), 1620–1630 (2015).Crossref, Medline, CAS, Google Scholar
12. Otto DP, Otto A, De Villiers MM. Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery. Expert Opin. Drug Deliv. 12(5), 763–777 (2015). • Emphasizes the impact of physicochemical properties on nanosized drug delivery systems.Crossref, Medline, CAS, Google Scholar
13. Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J. Nanomater. 2011, 11 (2011).Crossref, Google Scholar
14. Esfandyari-Manesh M, Darvishi B, Ishkuh FA et al. Paclitaxel molecularly imprinted polymer-PEG-folate nanoparticles for targeting anticancer delivery: characterization and cellular cytotoxicity. Mater. Sci. Eng. C Mater. Biol. Appl. 62, 626–633 (2016).Crossref, Medline, CAS, Google Scholar
15. Devulapally R, Foygel K, Sekar TV, Willmann JK, Paulmurugan R. Gemcitabine and antisense-microRNA co-encapsulated PLGA-PEG polymer nanoparticles for hepatocellular carcinoma therapy. ACS Appl. Mater. Interfaces 8(49), 33412–33422 (2016).Crossref, Medline, CAS, Google Scholar
16. Surnar B, Sharma K, Jayakannan M. Core–shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells. Nanoscale 7(42), 17964–17979 (2015).Crossref, Medline, CAS, Google Scholar
17. Ye YJ, Wang Y, Lou KY, Chen YZ, Chen R, Gao F. The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes. Int. J. Nanomedicine 10, 4309–4319 (2015).Medline, CAS, Google Scholar
18. Bowerman CJ, Byrne JD, Chu KS et al. Docetaxel-loaded PLGA nanoparticles improve efficacy in taxane-resistant triple-negative breast cancer. Nano. Lett. 17(1), 242–248 (2017). • Demonstrates the antitumor effect of poly(lac-tic-co-glycolic acid)-docetaxel nanoparticles.Crossref, Medline, CAS, Google Scholar
19. Khanna C, Rosenberg M, Vail DM. A review of paclitaxel and novel formulations including those suitable for use in dogs. J. Vet. Intern. Med. 29(4), 1006–1012 (2015).Crossref, Medline, CAS, Google Scholar
20. Palumbo R, Sottotetti F, Trifiro G et al. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des. Devel. Ther. 9, 2189–2199 (2015).Crossref, Medline, CAS, Google Scholar
21. Denkert C, Von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 33(9), 983–991 (2015).Crossref, Medline, CAS, Google Scholar
22. Kita-Tokarczyk K, Grumelard J, Haefele T, Meier W. Block copolymer vesicles – using concepts from polymer chemistry to mimic biomembranes. Polymer 46(11), 3540–3563 (2005).Crossref, CAS, Google Scholar
23. Ghaffar KA, Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposomes as nanovaccine delivery systems. Curr. Top. Med. Chem. 14(9), 1194–1208 (2014).Crossref, Medline, Google Scholar
24. Reynolds JG, Geretti E, Hendriks BS et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol. Appl. Pharmacol. 262(1), 1–10 (2012).Crossref, Medline, CAS, Google Scholar
25. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145–160 (2005).Crossref, Medline, CAS, Google Scholar
26. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42(5), 419–436 (2003).Crossref, Medline, CAS, Google Scholar
27. Khoshtinat Nikkhoi S, Rahbarizadeh F, Ahmadvand D, Moghimi SM. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: in vitro proof-of-concept. Eur. J. Pharm. Sci. 122, 42–50 (2018).Crossref, Medline, Google Scholar
28. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 63(6), 456–469 (2011).Crossref, Medline, CAS, Google Scholar
29. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 50(1), 161–177 (2000).Crossref, Medline, CAS, Google Scholar
30. Campos J, Varas-Godoy M, Haidar ZS. Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells. Nanomedicine 12(5), 473–490 (2017).Link, CAS, Google Scholar
31. Yuan Q, Han J, Cong W et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int. J. Nanomedicine 9, 4829–4846 (2014).Medline, Google Scholar
32. Baek J-S, Na Y-G, Cho C-W. Sustained cytotoxicity of wogonin on breast cancer cells by encapsulation in solid lipid nanoparticles. Nanomaterials 8(3), 159 (2018).Crossref, Google Scholar
33. Fangueiro JF, Andreani T, Fernandes L et al. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf. B Biointerfaces 123, 452–460 (2014).Crossref, Medline, CAS, Google Scholar
34. Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87(1), 1–18 (2014).Crossref, Medline, CAS, Google Scholar
35. Shi S, Han L, Deng L et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J. Control Rel. 194, 228–237 (2014).Crossref, Medline, CAS, Google Scholar
36. Deng H, Zhang Y, Wang X et al. Balancing the stability and drug release of polymer micelles by the coordination of dual-sensitive cleavable bonds in cross-linked core. Acta. Biomater. 11, 126–136 (2015).Crossref, Medline, CAS, Google Scholar
37. Zhang F, Zhang S, Pollack SF et al. Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. J. Am. Chem. Soc. 137(5), 2056–2066 (2015).Crossref, Medline, CAS, Google Scholar
38. Gulfam M, Matini T, Monteiro PF, Riva R, Collins H. Bioreducible cross-linked core polymer micelles enhance in vitro activity of methotrexate in breast cancer cells. Biomater. Sci. 5(3), 532–550 (2017).Crossref, Medline, CAS, Google Scholar
39. Zhong Y, Goltsche K, Cheng L et al. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials 84, 250–261 (2016).Crossref, Medline, CAS, Google Scholar
40. Beloqui A, Solinis MA, Rodriguez-Gascon A, Almeida AJ, Preat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 12(1), 143–161 (2016). • Describes the current state of the art of nanostructured lipid carriers as controlled drug delivery systems and discusses the major challenges in the use of nanostructured lipid carriers.Crossref, Medline, CAS, Google Scholar
41. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv. Pharm. Bull. 5(3), 305–313 (2015).Crossref, Medline, CAS, Google Scholar
42. Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials (Basel) 7(6), 122 (2017). •• introduces nanostructured lipid carriers, solid lipid nanoparticles and polymer nanoparticles. Crossref, Google Scholar
43. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54(Suppl. 1), S131–S155 (2002).Crossref, Medline, CAS, Google Scholar
44. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin. Drug Deliv. 9(5), 497–508 (2012).Crossref, Medline, CAS, Google Scholar
45. Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol. 7(1), 41–55 (2013).Crossref, Medline, CAS, Google Scholar
46. Yang Y, Corona A 3rd, Schubert B, Reeder R, Henson MA. The effect of oil type on the aggregation stability of nanostructured lipid carriers. J. Colloid Interface Sci. 418, 261–272 (2014).Crossref, Medline, CAS, Google Scholar
47. Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf. B. Biointerfaces 113, 15–24 (2014).Crossref, Medline, CAS, Google Scholar
48. Rahman HS, Rasedee A, How CW et al. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int. J. Nanomedicine 8, 2769–2781 (2013).Crossref, Medline, Google Scholar
49. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 70(2), 633–640 (2008).Crossref, Medline, CAS, Google Scholar
50. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B Biointerfaces 85(2), 262–269 (2011).Crossref, Medline, CAS, Google Scholar
51. Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in PEGylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J. Control Rel. 160(2), 245–253 (2012).Crossref, Medline, CAS, Google Scholar
52. Yang XZ, Dou S, Wang YC et al. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano 6(6), 4955–4965 (2012).Crossref, Medline, CAS, Google Scholar
53. Zheng Y, Yu B, Weecharangsan W et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells. Int. J. Pharm. 390(2), 234–241 (2010).Crossref, Medline, CAS, Google Scholar
54. Garg NK, Tyagi RK, Sharma G et al. Functionalized lipid–polymer hybrid nanoparticles mediated codelivery of methotrexate and aceclofenac: a synergistic effect in breast cancer with improved pharmacokinetics attributes. Mol. Pharm. 14(6), 1883–1897 (2017).Crossref, Medline, CAS, Google Scholar
55. Zhang L, Zhu D, Dong X et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int. J. Nanomedicine 10, 2101–2114 (2015).Medline, Google Scholar
56. Zhang RX, Cai P, Zhang T et al. Polymer–lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin–mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine 12(5), 1279–1290 (2016).Crossref, Medline, Google Scholar
57. Barenholz Y. Doxil(R) – the first FDA-approved nano-drug: lessons learned. J. Control Rel. 160(2), 117–134 (2012).Crossref, Medline, CAS, Google Scholar
58. Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control Rel. 244(Pt A), 108–121 (2016). •• Emphasizes the current state of the enhanced permeability and retention effect. Discusses the relationship between tumor targeting and the tumor microenvironment.Crossref, Medline, CAS, Google Scholar
59. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev. Drug Discov. 9(8), 615–627 (2010).Crossref, Medline, CAS, Google Scholar
60. Singh AV, Raichur AM, Dyawanapelly S. Conjugates, polymer–drug: targeted cancer treatment. Encyclopedia of Biomedical Polymers and Polymeric Biomaterial. Taylor and Francis, New York, USA, 2089–2112 (2015).Google Scholar
61. Tang X, Loc WS, Dong C et al. The use of nanoparticulates to treat breast cancer. Nanomedicine (Lond.) 12(19), 2367–2388 (2017).Link, CAS, Google Scholar
62. Anselmo AC, Mitragotri S. A review of clinical translation of inorganic nanoparticles. AAPS J. 17(5), 1041–1054 (2015).Crossref, Medline, CAS, Google Scholar
63. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1(1), 10–29 (2016).Crossref, Medline, Google Scholar
64. Wilhelm S, Tavares AJ, Dai Q et al. Analysis of nanoparticle delivery to tumors. Nat. Rev. Mater. 1, 16014 (2016).Crossref, CAS, Google Scholar
65. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136–151 (2011).Crossref, Medline, CAS, Google Scholar
66. Maeda H. Polymer therapeutics and the EPR effect. J. Drug Target. 25(9–10), 781–785 (2017).Crossref, Medline, CAS, Google Scholar
67. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J. Drug Target. 24(3), 179–191 (2016).Crossref, Medline, CAS, Google Scholar
68. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1–16 (2012).Crossref, Medline, CAS, Google Scholar
69. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263(5153), 1600–1603 (1994).Crossref, Medline, CAS, Google Scholar
70. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano lett. 9(5), 1909–1915 (2009).Crossref, Medline, CAS, Google Scholar
71. Sanchez-Moreno P, Buzon P, Boulaiz H et al. Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. Biomaterials 61, 266–278 (2015).Crossref, Medline, CAS, Google Scholar
72. Badawy AME, Luxton TP, Silva RG, Scheckel KG, Suidan MT, Tolaymat TM. Impact of environmental conditions (pH, ionic strength, and electrolyte type) on the surface charge and aggregation of silver nanoparticles suspensions. Environ. Sci. Technol. 44(4), 1260–1266 (2010).Crossref, Medline, Google Scholar
73. Suman TY, Rajasree SRR, Jayaseelan C et al. GC-MS analysis of bioactive components and biosynthesis of silver nanoparticles using Hybanthus enneaspermus at room temperature evaluation of their stability and its larvicidal activity. Environ. Sci. Pollut. Res. Int. 23(3), 2705–2714 (2016).Crossref, Medline, CAS, Google Scholar
74. Sun Q, Cai X, Li J, Zheng M, Chen Z, Yu C-P. Green synthesis of silver nanoparticles using tea leaf extract and evaluation of their stability and antibacterial activity. Colloids Surf. A Physicochem. Eng. Asp. 444, 226–231 (2014).Crossref, CAS, Google Scholar
75. Shi C, Zhang Z, Wang F, Ji X, Zhao Z, Luan Y. Docetaxel-loaded PEO–PPO–PCL/TPGS mixed micelles for overcoming multidrug resistance and enhancing antitumor efficacy. J. Mater. Chem. B 3(20), 4259–4271 (2015).Crossref, Medline, CAS, Google Scholar
76. Guo Y, He W, Yang S, Zhao D, Li Z, Luan Y. Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer. Colloids Surf. B Biointerfaces 151, 119–127 (2017).Crossref, Medline, CAS, Google Scholar
77. Nikpoor AR, Tavakkol-Afshari J, Gholizadeh Z et al. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. Int. J. Pharm. 495(1), 162–170 (2015).Crossref, Medline, CAS, Google Scholar
78. Abbasi S, Paul A, Shao W, Prakash S. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J. Drug Deliv. 2012, 686108 (2012).Medline, Google Scholar
79. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control Rel. 161(2), 175–187 (2012).Crossref, Medline, CAS, Google Scholar
80. Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J. Cancer Res. Clin. Oncol. 141(5), 769–784 (2015).Crossref, Medline, CAS, Google Scholar
81. Xu H, Aguilar ZP, Yang L et al. Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials 32(36), 9758–9765 (2011).Crossref, Medline, CAS, Google Scholar
82. Mu Q, Kievit FM, Kant RJ, Lin G, Jeon M, Zhang M. Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. Nanoscale 7(43), 18010–18014 (2015).Crossref, Medline, CAS, Google Scholar
83. Wolff AC, Wang M, Li H et al. Phase II trial of PEGylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res. Treat. 121(1), 111–120 (2010).Crossref, Medline, CAS, Google Scholar
84. Brinkman AM, Chen G, Wang Y et al. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 101, 20–31 (2016).Crossref, Medline, CAS, Google Scholar
85. Jin H, Pi J, Zhao Y et al. EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy. Nanoscale 9(42), 16365–16374 (2017).Crossref, Medline, CAS, Google Scholar
86. Singh SK, Singh S, Lillard JW Jr., Singh R. Drug delivery approaches for breast cancer. Int. J. Nanomedicine 12, 6205–6218 (2017).Crossref, Medline, CAS, Google Scholar
87. Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31(8), 2278–2292 (2010).Crossref, Medline, CAS, Google Scholar
88. Feng Q, Yu M-Z, Wang J-C et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core–shell nanoparticles. Biomaterials 35(18), 5028–5038 (2014).Crossref, Medline, CAS, Google Scholar
89. Xiang D, Shigdar S, Qiao G et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics 5(1), 23–42 (2015).Crossref, Medline, Google Scholar
90. Ngamcherdtrakul W, Morry J, Gu S et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER²⁺ breast cancer. Adv. Funct. Mater. 25(18), 2646–2659 (2015).Crossref, Medline, CAS, Google Scholar
91. Song X, Ren Y, Zhang J et al. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes. Oncol. Rep. 34(4), 1953–1960 (2015).Crossref, Medline, CAS, Google Scholar
92. Gunduz U, Keskin T, Tansik G et al. Idarubicin-loaded folic acid conjugated magnetic nanoparticles as a targetable drug delivery system for breast cancer. Biomed. Pharmacother. 68(6), 729–736 (2014).Crossref, Medline, CAS, Google Scholar
93. Ding L, Li J, Huang R et al. Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO₂; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO₂ nanoparticles. Int. J. Nanomedicine 11, 5709–5727 (2016).Crossref, Medline, Google Scholar
94. Banu H, Sethi DK, Edgar A et al. Doxorubicin loaded polymeric gold nanoparticles targeted to human folate receptor upon laser photothermal therapy potentiates chemotherapy in breast cancer cell lines. J. Photochem. Photobiol. B 149, 116–128 (2015).Crossref, Medline, CAS, Google Scholar
95. Koning GA, Eggermont AM, Lindner LH, Ten Hagen TL. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm. Res. 27(8), 1750–1754 (2010).Crossref, Medline, CAS, Google Scholar
96. Lale SV, Kumar A, Naz F, Bharti AC, Koul V. Multifunctional ATRP based pH responsive polymeric nanoparticles for improved doxorubicin chemotherapy in breast cancer by proton sponge effect/endo-lysosomal escape. Polym. Chem. 6(11), 2115–2132 (2015).Crossref, CAS, Google Scholar
97. Kocbek P, Kralj S, Kreft ME, Kristl J. Targeting intracellular compartments by magnetic polymeric nanoparticles. Eur. J. Pharm. Sci. 50(1), 130–138 (2013).Crossref, Medline, CAS, Google Scholar
98. Rudokas M, Najlah M, Alhnan MA, Elhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med. Princ. Pract. 25(Suppl. 2), 60–72 (2016).Crossref, Medline, Google Scholar
99. Jahanshahi M, Aghajani H, Ling TC. Assembly and purification of nanostructure bioproducts: protein nanoparticle characterizations and non-stick exterior coating adsorbents. Int. J. Nanoscience Nanotechnology (IJNN) 1(1), 9–19 (2005).Google Scholar
100. Cho W-S, Cho M, Jeong J et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol. 245(1), 116–123 (2010).Crossref, Medline, CAS, Google Scholar
101. Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications and toxicities. Arab. J. Chem. (2017). doi:10.1016/j.arabjc.2017.05.011 (In press).Crossref, Google Scholar
102. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J. Nanobiotechnology 11, 26 (2013).Crossref, Medline, CAS, Google Scholar
103. Liu Y, Rohrs J, Wang P. Advances and challenges in the use of nanoparticles to optimize PK/PD interactions of combined anti-cancer therapies. Curr. Drug Metab. 15(8), 818–828 (2014).Crossref, Medline, CAS, Google Scholar
104. Rodallec A, Fanciullino R, Lacarelle B, Ciccolini J. Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles. Expert Rev. Clin. Pharmacol. 11(6), 599–610 (2018).Crossref, Medline, CAS, Google Scholar

Vol. 14, No. 13

Metrics

Downloaded 343 times

History

Received 13 December 2018

Accepted 3 April 2019

Published online 12 July 2019

Published in print July 2019

Information

Keywords

Author contributions

M Du, F Meng and Y Ouyang contributed to writing the original draft, reviewing and editing. Q Ma, H Liu, Y Zhuang and M Pang were responsible for investigation and resources. T Cai and Y Cai carrried out supervision.

Financial & competing interests disclosure

This review was financially supported by the National Natural Science Foundation of China (81173215, 81273707); the Natural Science Foundation of Guangdong (2016A030311037); the Science and Technology Program of Guangzhou (2014J4500005, 201704030141); the Science Program of the Department of Education of Guangdong (2015KGJHZ012); the Science and Technology Program of Guangdong (2015A050502027); and the Special Project of International Scientific and Technological Cooperation in Guangzhou Development District (2017GH16). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was provided by EssayStar and was funded by the above funding.

PDF download